Congratulations to Precision's Darren W. Davis, PhD on his presentation at AMP yesterday with Agena Bioscience presenting methods to bridge critical gaps in detecting mutations not identified by next-generation sequencing (NGS) alone. Got questions for Darren or our team? Stop by Booth 1311 or reach out to set up time to speak with Darren Davis, Glen Ferguson, Rob Fannon, Kristi Garner and Brian Hart. #AMP2024
Precision For Medicine
Biotechnology Research
Bethesda, MD 140,000 followers
About us
Precision for Medicine is an industry-leading global clinical research services organization, purpose-built to improve the clinical research and development process for new therapeutics. Our novel approach integrates clinical operations excellence, with laboratory expertise, and advanced data sciences to inform every step. This maximizes our clients’ insight into patient biology, delivering more predictable trial outcomes and accelerating clinical development. We apply our expertise to trials at all stages—from early development through approval—with embedded experience in oncology and rare disease. With over 2000 dedicated professionals and 35 offices worldwide, we stand ready to help accelerate life-changing treatments anywhere around the globe.
- Website
-
http://www.precisionformedicine.com
External link for Precision For Medicine
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Bethesda, MD
- Type
- Privately Held
- Specialties
- Global Clinical Trial Services, Specialty Lab Services, Translational Science, Clinical Data Management, Biostatistics, Biomarker Strategies, Sample Sourcing and Storage, Immune Monitoring, IVD Development, CDx Development, Market Access, IVD CRO, Regulatory Strategy and Submission, and Contract Research Organization
Locations
-
Primary
2 Bethesda Metro Center
Suite 850
Bethesda, MD 20814, US
-
8425 Progress Drive
Fredrick, MD 21701, US
-
55 Cambridge Parkway
Ste 300E
Cambridge, MA 02142, US
Employees at Precision For Medicine
Updates
-
NEW FDA VIDEO ROUNDUP: In the latest edition of CMO Confidential, Harpreet Singh, MD, discusses the notable regulatory milestones in oncology and rare disease treatments from October. The FDA's approval of Zolbetuximab (Vyloy) for gastric and gastroesophageal junction adenocarcinoma marked a step forward in targeted therapies, particularly for patients with CLDN18.2 expression. This approval highlights the importance of biomarker-driven treatments in oncology and has implications for the future. The FDA released an update on the Rare Disease Innovation Hub aimed at streamlining the development of treatments for rare diseases. See why this is good news for innovators in the rare disease space. In hematology, Asciminib (Scemblix) received accelerated approval for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia. The substantial improvements in response rates compared to the investigator-selected tyrosine kinase inhibitors (IS-TKIs) is very noteworthy. Watch now and follow Harpreet Singh, MD for future insights.
-
Why are global drug developers choosing Australia to expedite clinical trials? (The answer goes beyond regulations.) Australia is known for its efficient trial environment, but navigating its unique landscape requires expertise. In this article, we explore the processes, partnerships, and precision that allow us to get trials up and running faster than ever. Read up on down under: https://hubs.ly/Q02Z1NTC0 #australia #clinicaltrials #clinicalresearch
-
The Precision team would love to meet you at EBF this week! Stop by Booth 2H or reach out to set up time to speak with Mandy Higgins or Astrid Grunwald.
-
Is your lab future-ready? Become more confident about your state of readiness with pragmatic insights from our Chief Scientific Officer, Deb Phippard, in her new article in Today's Clinical Lab. https://hubs.ly/Q02YVqND0 #biomarkers #precisionmedicine #clinicaltrials #oncology
-
Check out the latest video from Project Farma (PF) President Anshul Mangal as he covers key developments shaping biotech and pharma manufacturing. Key highlights: - Election Impacts - CAR-T Investment Surge - Radiopharma Advancements How do you see these changes influencing the future of biotech? Drop your thoughts in the comments! #ManufacturingMilestones #Biotech #CAR-T #Radiopharma #IndustryInsights
-
Exciting news coming out of AMP 2024: Announcing a strategic partnership and presentation with Agena Bioscience to bridge critical gaps in detecting mutations not identified by next-generation sequencing (NGS) alone. https://hubs.ly/Q02YV2-10 #AMP #next-generation sequencing
-
Harness precision medicine data intelligence with the power of conversation. With QuartzBio's Biomarker Intelligence Platform, we’re changing the way data science and R&D IT teams interact with and extract value from sample and biomarker data with 360° intelligence. Learn more at https://hubs.ly/Q02YHC9f0 #datascience #biopharma #clinicaltrials #AI
-
𝗟𝗶𝘃𝗲 𝗧𝗼𝗺𝗼𝗿𝗿𝗼𝘄! In this webinar, Precision for Medicine experts will reveal how a unified immunogenicity strategy can streamline your path to global approval, saving you valuable time and resources. Register now and ask your questions during the live Q&A session! https://hubs.ly/Q02YwMpm0 #genetherapy #clinicaltrials